Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases

Summary by Watauga Democrat
Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and OrizaProceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis

39 Articles

keenesentinel.comkeenesentinel.com
+38 Reposted by 38 other sources
Center

Accro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases

Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and OrizaProceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor for Ulcerative Colitis

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 68% of the sources are Center
68% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States on Tuesday, May 19, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Keene, New Hampshire icon

Keene, New Hampshire

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal